Abstract Treatment options are limited for multiple myeloma patients who have developed
four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were
recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs
is a concern since these agents are used in patients who have already undergone multiple
lines of treatment. In this review, we discuss the toxicity profile and strategies for the
management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a …

e20014 Background: Selinexor (Sel) and belantamab mafodotin (belamaf) were recently
approved by the US FDA for treatment of relapsed/refractory multiple myeloma on July 2019
and August 2020 respectively. The toxicity profile of these drugs is a concern since these are
approved for use in patients who have already undergone multiple lines of treatment.
Methods: Six studies for Sel and two for belamaf were included after a systematic search of
PubMed, Embase, Cochrane, and Clinicaltrials. gov. Results: The most common …